China Biosimilar Monoclonal Antibodies Market Report & Forecast 2021-2027

Publisher Name :
Date: 17-Aug-2021
No. of pages: 90
Inquire Before Buying

This report contains market size and forecasts of Biosimilar Monoclonal Antibodies in China, including the following market information:

China Biosimilar Monoclonal Antibodies Market Revenue, 2016-2021, 2022-2027, ($ millions)

China Biosimilar Monoclonal Antibodies Market Sales, 2016-2021, 2022-2027, (K Units)

China top five Biosimilar Monoclonal Antibodies companies in 2020 (%)

The global Biosimilar Monoclonal Antibodies market size is expected to growth from US$ 3666 million in 2020 to US$ 27030 million by 2027; it is expected to grow at a CAGR of 33.2% during 2021-2027.

The China Biosimilar Monoclonal Antibodies market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.

QYResearch has surveyed the Biosimilar Monoclonal Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

China Biosimilar Monoclonal Antibodies Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)

China Biosimilar Monoclonal Antibodies Market Segment Percentages, By Type, 2020 (%)

- Infliximab

- Rituximab

- Trastuzumab

- Adalimumab

- Other

China Biosimilar Monoclonal Antibodies Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)

China Biosimilar Monoclonal Antibodies Market Segment Percentages, By Application, 2020 (%)

- Oncology

- Autoimmune Disease

- Other

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Biosimilar Monoclonal Antibodies revenues in China market, 2016-2021 (Estimated), ($ millions)

Key companies Biosimilar Monoclonal Antibodies revenues share in China market, 2020 (%)

Key companies Biosimilar Monoclonal Antibodies sales in China market, 2016-2021 (Estimated), (K Units)

Key companies Biosimilar Monoclonal Antibodies sales share in China market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

- Celltrion

- Pfizer (Hospira)

- 3SBIO

- Novartis (Sandoz)

- Dr Reddy's

- Celgen Biopharma

- Cadila Healthcare

- Hisun Pharma

- Torrent Pharmaceuticals

China Biosimilar Monoclonal Antibodies Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Biosimilar Monoclonal Antibodies Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Biosimilar Monoclonal Antibodies Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 China Biosimilar Monoclonal Antibodies Overall Market Size
2.1 China Biosimilar Monoclonal Antibodies Market Size: 2021 VS 2027
2.2 China Biosimilar Monoclonal Antibodies Revenue, Prospects & Forecasts: 2016-2027
2.3 China Biosimilar Monoclonal Antibodies Sales: 2016-2027
3 Company Landscape
3.1 Top Biosimilar Monoclonal Antibodies Players in China Market
3.2 Top China Biosimilar Monoclonal Antibodies Companies Ranked by Revenue
3.3 China Biosimilar Monoclonal Antibodies Revenue by Companies
3.4 China Biosimilar Monoclonal Antibodies Sales by Companies
3.5 China Biosimilar Monoclonal Antibodies Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Biosimilar Monoclonal Antibodies Companies in China Market, by Revenue in 2020
3.7 Manufacturers Biosimilar Monoclonal Antibodies Product Type
3.8 Tier 1, Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Players in China Market
3.8.1 List of Tier 1 Biosimilar Monoclonal Antibodies Companies in China
3.8.2 List of Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Companies in China
4 Sights by Type
4.1 Overview
4.1.1 By Type - China Biosimilar Monoclonal Antibodies Market Size Markets, 2021 & 2027
4.1.2 Infliximab
4.1.3 Rituximab
4.1.4 Trastuzumab
4.1.5 Adalimumab
4.1.6 Other
4.2 By Type - China Biosimilar Monoclonal Antibodies Revenue & Forecasts
4.2.1 By Type - China Biosimilar Monoclonal Antibodies Revenue, 2016-2021
4.2.2 By Type - China Biosimilar Monoclonal Antibodies Revenue, 2022-2027
4.2.3 By Type - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
4.3 By Type - China Biosimilar Monoclonal Antibodies Sales & Forecasts
4.3.1 By Type - China Biosimilar Monoclonal Antibodies Sales, 2016-2021
4.3.2 By Type - China Biosimilar Monoclonal Antibodies Sales, 2022-2027
4.3.3 By Type - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
4.4 By Type - China Biosimilar Monoclonal Antibodies Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - China Biosimilar Monoclonal Antibodies Market Size, 2021 & 2027
5.1.2 Oncology
5.1.3 Autoimmune Disease
5.1.4 Other
5.2 By Application - China Biosimilar Monoclonal Antibodies Revenue & Forecasts
5.2.1 By Application - China Biosimilar Monoclonal Antibodies Revenue, 2016-2021
5.2.2 By Application - China Biosimilar Monoclonal Antibodies Revenue, 2022-2027
5.2.3 By Application - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
5.3 By Application - China Biosimilar Monoclonal Antibodies Sales & Forecasts
5.3.1 By Application - China Biosimilar Monoclonal Antibodies Sales, 2016-2021
5.3.2 By Application - China Biosimilar Monoclonal Antibodies Sales, 2022-2027
5.3.3 By Application - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
5.4 By Application - China Biosimilar Monoclonal Antibodies Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Celltrion
6.1.1 Celltrion Corporation Information
6.1.2 Celltrion Overview
6.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Description
6.1.5 Celltrion Recent Developments
6.2 Pfizer (Hospira)
6.2.1 Pfizer (Hospira) Corporation Information
6.2.2 Pfizer (Hospira) Overview
6.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Description
6.2.5 Pfizer (Hospira) Recent Developments
6.3 3SBIO
6.3.1 3SBIO Corporation Information
6.3.2 3SBIO Overview
6.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Description
6.3.5 3SBIO Recent Developments
6.4 Novartis (Sandoz)
6.4.1 Novartis (Sandoz) Corporation Information
6.4.2 Novartis (Sandoz) Overview
6.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Description
6.4.5 Novartis (Sandoz) Recent Developments
6.5 Dr Reddy's
6.5.1 Dr Reddy's Corporation Information
6.5.2 Dr Reddy's Overview
6.5.3 Dr Reddy's Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.5.4 Dr Reddy's Biosimilar Monoclonal Antibodies Product Description
6.5.5 Dr Reddy's Recent Developments
6.6 Celgen Biopharma
6.6.1 Celgen Biopharma Corporation Information
6.6.2 Celgen Biopharma Overview
6.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Description
6.6.5 Celgen Biopharma Recent Developments
6.7 Cadila Healthcare
6.7.1 Cadila Healthcare Corporation Information
6.7.2 Cadila Healthcare Overview
6.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Description
6.7.5 Cadila Healthcare Recent Developments
6.8 Hisun Pharma
6.8.1 Hisun Pharma Corporation Information
6.8.2 Hisun Pharma Overview
6.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Description
6.8.5 Hisun Pharma Recent Developments
6.9 Torrent Pharmaceuticals
6.9.1 Torrent Pharmaceuticals Corporation Information
6.9.2 Torrent Pharmaceuticals Overview
6.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Description
6.9.5 Torrent Pharmaceuticals Recent Developments
7 China Biosimilar Monoclonal Antibodies Production Capacity, Analysis
7.1 China Biosimilar Monoclonal Antibodies Production Capacity, 2016-2027
7.2 Biosimilar Monoclonal Antibodies Production Capacity of Key Manufacturers in China Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Biosimilar Monoclonal Antibodies Supply Chain Analysis
9.1 Biosimilar Monoclonal Antibodies Industry Value Chain
9.2 Biosimilar Monoclonal Antibodies Upstream Market
9.3 Biosimilar Monoclonal Antibodies Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Biosimilar Monoclonal Antibodies Distributors and Sales Agents in China Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Biosimilar Monoclonal Antibodies in China Market
Table 2. Top Biosimilar Monoclonal Antibodies Players in China Market, Ranking by Revenue (2019)
Table 3. China Biosimilar Monoclonal Antibodies Revenue by Companies, (US$, Mn), 2016-2021
Table 4. China Biosimilar Monoclonal Antibodies Revenue Share by Companies, 2016-2021
Table 5. China Biosimilar Monoclonal Antibodies Sales by Companies, (K Units), 2016-2021
Table 6. China Biosimilar Monoclonal Antibodies Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Biosimilar Monoclonal Antibodies Price (2016-2021) & (USD/Unit)
Table 8. Manufacturers Biosimilar Monoclonal Antibodies Product Type
Table 9. List of Tier 1 Biosimilar Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Infliximab
Table 12. Major Manufacturers of Rituximab
Table 13. By Type - China Biosimilar Monoclonal Antibodies Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2016-2021
Table 15. By Type - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2022-2027
Table 16. By Type - China Biosimilar Monoclonal Antibodies Sales (K Units), 2016-2021
Table 17. By Type - China Biosimilar Monoclonal Antibodies Sales (K Units), 2022-2027
Table 18. By Application - China Biosimilar Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2016-2021
Table 20. By Application - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2022-2027
Table 21. By Application - China Biosimilar Monoclonal Antibodies Sales (K Units), 2016-2021
Table 22. By Application - China Biosimilar Monoclonal Antibodies Sales (K Units), 2022-2027
Table 23. Celltrion Corporation Information
Table 24. Celltrion Description and Major Businesses
Table 25. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 26. Celltrion Biosimilar Monoclonal Antibodies Product
Table 27. Celltrion Recent Developments
Table 28. Pfizer (Hospira) Corporation Information
Table 29. Pfizer (Hospira) Description and Major Businesses
Table 30. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 31. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product
Table 32. Pfizer (Hospira) Recent Developments
Table 33. 3SBIO Corporation Information
Table 34. 3SBIO Description and Major Businesses
Table 35. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 36. 3SBIO Biosimilar Monoclonal Antibodies Product
Table 37. 3SBIO Recent Developments
Table 38. Novartis (Sandoz) Corporation Information
Table 39. Novartis (Sandoz) Description and Major Businesses
Table 40. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 41. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product
Table 42. Novartis (Sandoz) Recent Developments
Table 43. Dr Reddy's Corporation Information
Table 44. Dr Reddy's Description and Major Businesses
Table 45. Dr Reddy's Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 46. Dr Reddy's Biosimilar Monoclonal Antibodies Product
Table 47. Dr Reddy's Recent Developments
Table 48. Celgen Biopharma Corporation Information
Table 49. Celgen Biopharma Description and Major Businesses
Table 50. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 51. Celgen Biopharma Biosimilar Monoclonal Antibodies Product
Table 52. Celgen Biopharma Recent Developments
Table 53. Cadila Healthcare Corporation Information
Table 54. Cadila Healthcare Description and Major Businesses
Table 55. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 56. Cadila Healthcare Biosimilar Monoclonal Antibodies Product
Table 57. Cadila Healthcare Recent Developments
Table 58. Hisun Pharma Corporation Information
Table 59. Hisun Pharma Description and Major Businesses
Table 60. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 61. Hisun Pharma Biosimilar Monoclonal Antibodies Product
Table 62. Hisun Pharma Recent Developments
Table 63. Torrent Pharmaceuticals Corporation Information
Table 64. Torrent Pharmaceuticals Description and Major Businesses
Table 65. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 66. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product
Table 67. Torrent Pharmaceuticals Recent Developments
Table 68. Biosimilar Monoclonal Antibodies Production Capacity (K Units) of Key Manufacturers in China Market, 2019-2021 (K Units)
Table 69. China Biosimilar Monoclonal Antibodies Capacity Market Share of Key Manufacturers, 2019-2021
Table 70. Biosimilar Monoclonal Antibodies Market Opportunities & Trends in China Market
Table 71. Biosimilar Monoclonal Antibodies Market Drivers in China Market
Table 72. Biosimilar Monoclonal Antibodies Market Restraints in China Market
Table 73. Biosimilar Monoclonal Antibodies Raw Materials
Table 74. Biosimilar Monoclonal Antibodies Raw Materials Suppliers in China Market
Table 75. Typical Biosimilar Monoclonal Antibodies Downstream
Table 76. Biosimilar Monoclonal Antibodies Downstream Clients in China Market
Table 77. Biosimilar Monoclonal Antibodies Distributors and Sales Agents in China Market
List of Figures
Figure 1. Biosimilar Monoclonal Antibodies Product Picture
Figure 2. Biosimilar Monoclonal Antibodies Segment by Type
Figure 3. Biosimilar Monoclonal Antibodies Segment by Application
Figure 4. China Biosimilar Monoclonal Antibodies Market Overview: 2020
Figure 5. China Biosimilar Monoclonal Antibodies Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. China Biosimilar Monoclonal Antibodies Revenue, 2016-2027 (US$, Mn)
Figure 7. Biosimilar Monoclonal Antibodies Sales in China Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Biosimilar Monoclonal Antibodies Revenue in 2020
Figure 9. Infliximab Product Picture
Figure 10. Rituximab Product Picture
Figure 11. Trastuzumab Product Picture
Figure 12. Adalimumab Product Picture
Figure 13. Other Product Picture
Figure 14. By Type - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
Figure 15. By Type - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
Figure 16. By Type - China Biosimilar Monoclonal Antibodies Price (USD/Unit), 2016-2027
Figure 17. Oncology
Figure 18. Autoimmune Disease
Figure 19. Other
Figure 20. By Application - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
Figure 21. By Application - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
Figure 22. By Application - China Biosimilar Monoclonal Antibodies Price (USD/Unit), 2016-2027
Figure 23. Celltrion Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. 3SBIO Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Dr Reddy's Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Celgen Biopharma Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Cadila Healthcare Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Hisun Pharma Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. China Biosimilar Monoclonal Antibodies Production Capacity (K Units), 2016-2027
Figure 33. Biosimilar Monoclonal Antibodies Industry Value Chain
Figure 34. Marketing Channels
  • Global Biologics and Biosimilars Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 147
    According to our LPI (LP Information) latest study, the global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the futu......
  • Global Biosimilar Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Biosimilar Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Biosimilar Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Biosimilar Drug market. Biosimilar Drug are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Biologics and Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 147
    According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at USD 481830 million in 2023 and is forecast to a readjusted size of USD 842330 million by 2030 with a CAGR of 8.3% during review period. Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin......
  • Global Biosimilars Market Research Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 2680 Onwards        Pages: 167
    A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
  • Global Biosimilars Professional Survey Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 3280 Onwards        Pages: 133
    A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
  • Global Biosimilars Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Biosimilars market: According to our latest research, the global Biosimilars market looks promising in the next 5 years. As of 2022, the global Biosimilars market was estimated at USD 8203.97 million, and it's anticipated to reach USD 40650.01 million in 2028, with a CAGR of 30.57% during the forecast years. A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA?approved biologic product......
  • Global Biologics and Biosimilars Professional Survey Report 2023, Forecast to 2028
    Published: 24-Nov-2023        Price: US 3280 Onwards        Pages: 134
    Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
  • Global Biologics and Biosimilars Market Research Report 2023, Forecast to 2028
    Published: 24-Nov-2023        Price: US 2680 Onwards        Pages: 160
    Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
  • Global Biosimilar Monoclonal Antibodies Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 103
    Market Overview of Global Biosimilar Monoclonal Antibodies market: According to our latest research, the global Biosimilar Monoclonal Antibodies market looks promising in the next 5 years. As of 2022, the global Biosimilar Monoclonal Antibodies market was estimated at USD 5156.19 million, and it's anticipated to reach USD 14274.14 million in 2028, with a CAGR of 18.5% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs